# Zoledronic Acid Combined With EC-T for Triple-Negative Breast Cancer

> **NCT06876636** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Xijing Hospital** · enrollment: 99 (estimated)

## Conditions studied

- Breast Cancer Metastatic

## Interventions

- **DRUG:** Zoledronic Acid Combined with Neoadjuvant Chemotherapy (EC-T)

## Key facts

- **NCT ID:** NCT06876636
- **Lead sponsor:** Xijing Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-03-10
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 99 (ESTIMATED)
- **Last updated:** 2025-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06876636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06876636, "Zoledronic Acid Combined With EC-T for Triple-Negative Breast Cancer". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT06876636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*